A Mayo Clinic study reveals that African Americans exhibit significantly higher antibody responses to the rubella vaccine compared to other populations. This finding challenges the "one size fits all" approach to immunology and supports the move toward personalized or individualized medicine. The legal classification of vaccines as "biologics" is also noted, which provides manufacturers with indemnification from lawsuits.